TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG

1 total filings · 0 classes · Active since Nov 2020

TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG holds 1 USPTO trademark filings across 0 NICE classes. The largest concentration is in Class 44 (Medical & Beauty Services) with 1 filings. The WikiTrademarks Expansion Score is 1/100, low — the brand is focused on defending its existing categories rather than expanding.

USPTO data refreshed June 21, 2026

Own this brand? Claim the profile to add your logo, story, and website.

Sign in to claim

How is TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG filing trademarks, and where is the portfolio expanding?

Filing Velocity (24 Months)

Jul 2024 Jun 2026

Nice Class Distribution

Activity Timeline

No activity recorded yet.

Recent Filings

Serial No. Mark Filing Date Status Classes Owner
90318619 TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG Nov 13, 2020 Pending 044 Medical & Beauty Services Genentech, Inc.
See how ChatGPT talks about TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG Beta

Weekly visibility reports showing how ChatGPT mentions TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG, where you rank in the answer, the sentiment of the mention, and which sources ChatGPT cites.

Join waitlist →

FAQ: TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark portfolio

What trademarks does TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG hold?

TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG holds 1 USPTO trademark filings across 0 NICE classes. The largest concentration is in Class 44 (Medical & Beauty Services). The most recent filings are registered to Genentech, Inc..

How many trademarks does TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG have at the USPTO?

WikiTrademarks tracks 1 USPTO trademark filings attributed to TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG. The brand has been actively filing since November 2020. The count updates daily as new filings are indexed from the USPTO bulk data feed.

In which NICE classes does TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG file most often?

TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG's most active class is NICE Class 44 (Medical & Beauty Services), with 1 filings. The full distribution across all 0 classes is shown in the Nice Class Distribution panel on this page.

Who owns the TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark?

The most recent filings under the TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG mark are registered to Genentech, Inc.. Trademark ownership can shift through assignments — see the Ownership & Assignment History section on this page for the full chain of title.

Is TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG expanding into new categories?

The current WikiTrademarks Expansion Score for TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG is 1 out of 100, which is low — the brand is focused on defending its existing categories rather than expanding. The score combines NICE class breadth, filing velocity, and the rate of cross-class movement from the brand's filing history.

How can I track new TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG trademark filings?

Click the Watch Brand button at the top of this page to add TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG to your Watchlist. New filings show up on your WikiTrademarks dashboard within 24 to 48 hours of being public, alongside any class expansions, status changes, or assignment events.

More on this portfolio: Compare TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG to another owner · Browse all NICE classes · Most valuable brands

Community notes

0 notes
Sign in to add a note

Share what you know about TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG and help the next person researching it.

No notes yet. Be the first to add what you know about TECENTRIQ ATEZOLIZUMAB INJECTION FOR INTRAVENOUS USE 1200 MG.